Related Experiment Videos
Is there a J curve distribution for diastolic blood pressure?
Insights
Investigating very low diastolic pressure in hypertension treatment reveals a debated "J-curve" effect. While potentially harmful in some cases, the primary benefit of hypertension management remains stroke risk reduction.
Area of Science:
- Cardiology
- Hypertension Research
- Clinical Trials
Background:
- The potential for harm from excessively low diastolic pressure during hypertension treatment is a significant clinical question.
- This
- J-curve
- hypothesis suggests increased cardiovascular mortality at very low diastolic pressures, potentially explaining trial failures in hypertension prevention.
Purpose of the Study:
- To review the evidence and debate surrounding the
- J-curve
- phenomenon in treated hypertension.
- To evaluate whether a diastolic pressure threshold exists below which treatment benefits are outweighed by harm.
Main Methods:
- Review of existing literature and clinical trial data on hypertension management.
- Analysis of studies investigating cardiovascular outcomes at varying levels of diastolic blood pressure.
Main Results:
- Evidence supporting the
- J-curve
- effect (harm from very low diastolic pressure) is not definitive.
- Alternative explanations for excess cardiovascular mortality at low diastolic pressures exist.
Conclusions:
- Both proponents and sceptics of the
- J-curve
- hypothesis may hold valid points.
- The potential presence of a
- J-curve
- should not overshadow the established benefit of hypertension treatment in reducing stroke risk.
Abstract:
The question whether there is a level of diastolic pressure during treatment below which further reduction of pressure may be harmful rather than beneficial is of great interest. If, as the proponents of this hypothesis maintain, death from CHD among treated hypertensives becomes more rather than less common at very low diastolic pressure, this might explain at least in part why most primary prevention trials of hypertension have failed to show a reduction in CHD mortality. However, as the sceptics have pointed out, the evidence that drug induced lowering of blood pressure is harmful is not of the highest quality, and alternative explanations for excess cardiovascular mortality at low diastolic pressure exist. In the following review of this hotly contested debate it is concluded that both proponents and sceptics may be correct, but that the presence of a J curve should not divert attention from the main benefit of treating hypertension which is a reduction in the risk of fatal and non fatal stroke.